The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Open accessAbstract
Kidney fibrosis is the final common pathway of all progressive chronic kidney diseases, of which diabetic nephropathy is the leading cause. Endothelial-to-mesenchymal transition (EndMT) has emerged as one of the most important origins of matrix-producing fibroblasts. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been introduced into the market as antidiabetes drugs. Here, we found that the DPP-4 inhibitor linagliptin ameliorated kidney fibrosis in diabetic mice without altering the blood glucose levels associated with the inhibition of EndMT and the restoration of microRNA 29s. Streptozotocin-induced diabetic CD-1 mice exhibited kidney fibrosis and strong immunoreactivity for DPP-4 by 24 weeks after the onset of diabetes. At 20 weeks after the onset of diabetes, mice were treated with linagliptin for 4 weeks. Linagliptin-treated diabetic mice exhibited a suppression of DPP-4 activity/protein expression and an amelioration of kidney fibrosis associated with the inhibition of EndMT. The therapeutic effects of linagliptin on diabetic kidneys were associated with the suppression of profibrotic programs, as assessed by mRNA microarray analysis. We found that the induction of DPP-4 observed in diabetic kidneys may be associated with suppressed levels of microRNA 29s in diabetic mice; linagliptin restored microRNA 29s and suppressed DPP-4 protein levels. Using cultured endothelial cells, we found that linagliptin inhibited TGF-β2–induced EndMT, and such anti-EndMT effects of linagliptin were mediated through microRNA 29 induction. These results indicate the possible novel pleiotropic action of linagliptin to restore normal kidney function in diabetic patients with renal impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Origin and function of myofibroblasts in kidney fibrosis
LeBleu, V. S., Taduri, G., O'Connell, J., Teng, Y., Cooke, V. G., Woda, C., Sugimoto, H., & Kalluri, R. (2013) · Nature Medicine · doi:10.1038/nm.3218 · Cited by 1,263
Tubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage
Nath, K. A. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80312-x · Cited by 974
Risdon, R. A., Sloper, J. C., & De Wardener, H. E. (1968) · The Lancet · doi:10.1016/s0140-6736(68)90589-8 · Cited by 668
The role of endothelial-to-mesenchymal transition in cancer progression
Potenta, S., Zeisberg, E., & Kalluri, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604662 · Cited by 554
miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis
Cushing, L., Kuang, P. P., Qian, J., Shao, F., Wu, J., Little, F., Thannickal, V. J., Cardoso, W. V., & Lü, J. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0323oc · Cited by 502
Jarett, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92801-9 · Cited by 495
Cited by
Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases
Piera-Velazquez, S., & Jimenez, S. A. (2019) · Physiological Reviews · doi:10.1152/physrev.00021.2018 · Cited by 662
Macro‐ and microvascular endothelial dysfunction in diabetes: 糖尿病诱导的内皮细胞功能损伤
Shi, Y., & Vanhoutte, P. M. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12521 · Cited by 545
Endothelium structure and function in kidney health and disease
Jourde-Chiche, N., Fakhouri, F., Dou, L., Bellien, J., Burtey, S., Frimat, M., Jarrot, P.-A., Kaplanski, G., Le Quintrec, M., Pernin, V., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0098-z · Cited by 493
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Cho, J. G., Lee, A., Chang, W., Lee, M.-S., & Kim, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00294 · Cited by 284
Yang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of Human Fibrotic Diseases
Piera-Velazquez, S., Mendoza, F., & Jimenez, S. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5040045 · Cited by 273
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Cooper, M. E., Perkovic, V., McGill, J. B., Groop, P.-H., Wanner, C., Rosenstock, J., Hehnke, U., Woerle, H.-J., & von Eynatten, M. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.024 · Cited by 110
Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62
Modelling and targeting mechanical forces in organ fibrosis
Mascharak, S., L. Guo, J., Griffin, M., E. Berry, C., C. Wan, D., & T. Longaker, M. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00144-3 · Cited by 59
Diabetic nephropathy: Time to withhold development and progression - A review
Sharaf El Din, U. A. A., Salem, M. M., & Abdulazim, D. O. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.004 · Cited by 53
MicroRNA profiling reveals distinct profiles for tissue-derived and cultured endothelial cells
Kuosmanen, S. M., Kansanen, E., Sihvola, V., & Levonen, A.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-11487-4 · Cited by 48
Tsai, T.-H., Lee, C.-H., Cheng, C.-I., Fang, Y.-N., Chung, S.-Y., Chen, S.-M., Lin, C.-J., Wu, C.-J., Hang, C.-L., & Chen, W.-Y. (2019) · Cells · doi:10.3390/cells8060589 · Cited by 37
Metadata
- Authors
- Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-05-15
- Volume
- 63
- Issue
- 6
- Pages
- 2120-2131
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2116878783
- Cited by
- 359
- References
- 38
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.